

INDEX

A

Activation-induced cytosine deaminase (AID) 145–146
 ADCC. *See* Antibody dependent cellular cytotoxicity (ADCC)
 Adjuvant 3, 9, 145
 Affinity 9, 13–16, 19–21, 23, 24, 54, 55, 89, 97–99, 102, 108–109, 115, 121, 137–139, 141, 145, 146, 178–180, 183, 184, 188–190, 192, 193, 196, 209–211, 213, 217–218, 226–228, 230, 236, 237, 255, 261, 277, 278, 287–289, 291, 292, 295, 297, 302
 Affinity maturation 13, 18, 20, 21, 55, 118, 139, 141, 142, 145, 147
 AID. *See* Activation-induced cytosine deaminase (AID)
 Alamar Blue 283, 291, 299, 300, 303, 307
 Albumin 2, 64, 82, 122, 163, 235, 250, 299
 Amine 37, 174, 289, 303, 305
 Animal model 21, 313
 Antibiotic 49, 279
 Antibody
 engineering 150, 184, 209
 fragment 12–15, 18–23, 34–42, 54, 192, 202, 233–245, 249–250, 266
 Antibody dependent cellular cytotoxicity (ADCC) 196, 210, 211, 213, 233, 234, 248, 250, 278, 279, 282–283, 290–292, 295, 297, 298, 304, 308–311
 Antigen 1–10, 12–14, 20, 21, 23, 24, 35–42, 44, 46–48, 50, 51, 54, 55, 82–95, 98, 109–112, 115, 117–120, 123, 124, 126–129, 132, 133, 137–142, 145, 149, 150, 168, 169, 171–181, 183–187, 189–193, 211, 213, 236, 248–252, 254, 257, 261, 268, 274, 286, 287, 291, 292, 295, 297, 302, 305, 307
 Antigen binding fragment (Fab) 13, 14, 16, 19, 34, 37, 41–51, 53–78, 81–99, 169, 197, 198, 209, 234–245, 251, 257, 292, 305
 Apoptosis 16, 234, 295, 300, 305–307, 312
 Association 172, 175, 179, 180, 235, 261, 269
 Association rate 180, 181, 184, 187, 189, 190, 192
 Autoantigen 57, 145
 Avidity 15, 54, 162, 178, 179, 261, 288, 292

B

BAC. *See* Bacterial artificial chromosome (BAC)
 Bacteria 6–9, 14, 35, 39–43, 46, 210, 211, 249–250, 254, 297
 Bacterial artificial chromosome (BAC) 144
 BALB/c 4, 124
 B cell/B-cell 13, 15, 20, 118, 137, 140–142, 144, 145, 150, 161–170, 283, 290
 B95.8 cell line 163
 B cell receptor (BCR) 140, 143, 144, 161, 162
 Bead 5, 35, 37–40, 48, 49, 91, 105, 109, 111, 165, 169, 302, 304
 Biacore 172–174, 176, 179, 184, 185, 187–189, 191, 253, 279, 282, 288–290, 300, 305.
See also Surface plasmon resonance (SPR)
 Bifunctional 22
 Binding 1–9, 12–14, 16, 17, 19, 20, 22, 34, 35, 37–39, 42, 48, 54, 56, 81, 92, 102, 106, 118, 121, 126, 129, 133, 138, 142, 149–150, 164, 168, 171–172, 174–181, 183, 184, 186–189, 193, 210, 211, 213, 234–236, 243, 248, 250–252, 254, 257, 261, 266, 268, 273–275, 277–292, 295, 297–299, 302, 303, 305–308
 Binding molecule 1–10, 12, 102, 172
 Biomarker 3, 5, 118
 Biosensor 174, 179
 Biotin 3, 48, 50, 97, 109
 Biotinylation 22, 37, 48, 86, 97, 109, 281, 291
 Bispecific 22, 247–261
 Bivalent 99, 177, 178, 234, 250, 254, 268
 BL21 5, 7
 Blocking 2, 15, 35, 37–38, 46–48, 82, 88, 92, 94, 97, 109, 121, 123, 128, 164, 169, 234, 267, 275, 305
 Blood 3, 55, 57, 58, 64, 65, 144, 157, 163, 164, 166, 169, 282, 283, 290, 297, 300, 304, 313
 Bone marrow mononuclear cells (BMMC) 55, 58, 64–65, 76, 77

C

Cancer 5, 13, 18, 53, 118, 211, 234–235, 247–249, 295, 311, 312

Capture..... 2, 35, 38, 39, 109–111, 171–177, 179–181, 185–187, 191, 192

Carbenicillin.....63, 72, 73, 76, 83, 85, 86, 88, 90, 94, 95, 214, 216, 218, 220–223, 228, 279, 284, 285

Carbohydrate..... 195, 196, 199–201, 204, 205, 278

Caspase.....18, 19, 299, 303, 314

C57BL6, 312

CD20, 163, 165–167, 170, 211–213, 305–306, 312

CDC. *See* Complement dependent cytotoxicity (CDC)

CDR. *See* Complementarity determining region (CDR)

Cell fusion 4, 9, 118–122, 124–126, 132
See also Fusion

Cell labeling 126

293 Cells.....253, 260, 267, 270, 273
See also Human embryonic kidney 293 cells (HEK 293 cells)

Chimeric antibody..... 144, 150

Chimerization 12, 118, 247

Chinese hamster ovary cells (CHO)..... 200, 278, 279, 281, 291

Chloramphenicol..... 34–36, 49

CHO. *See* Chinese hamster ovary cells (CHO)

Chromatography10, 98–99, 197–199, 210, 211, 213, 217–218, 226–228, 230, 241, 255, 260, 273, 302

Citrine267–275

Class switching.....138, 140, 144, 150

Class switch recombination 150, 165

Clearance.....234, 248

Clinical development.....15, 144, 145, 236

Clinical trial..... 15, 18, 118, 146, 235, 248, 295

Cloning..... 13, 14, 42, 54–57, 99, 118, 129–130, 133, 152, 162, 164, 168, 209–231, 254

Coat protein5, 14–15, 54, 56, 104

Competent cells..... 5, 7, 35, 36, 45, 220, 222, 223, 279, 285

Complement..... 196, 210, 233, 278, 283, 291, 295, 297, 298, 300–301, 307–308, 311, 312

Complementarity determining region (CDR)..... 14, 20, 21, 23, 57, 106, 184, 191, 210

Complement dependent cytotoxicity (CDC)..... 210, 211, 213, 233, 234, 278, 279, 283, 290–292, 295, 298, 307

Conjugation.....235, 236, 238, 244, 248, 249, 265–266, 303

Constant region..... 137, 138, 140, 143, 144, 150, 154, 250, 296

Construct.....5, 13, 102–104, 106–108, 113, 114, 254, 257

Coupling.... 2, 12, 34, 102, 174, 250, 266, 282, 289, 302, 305

C1q.....278, 298, 301, 307, 308

Cre recombinase..... 155

See also LoxP

CrossMab.....251, 252, 257–259, 261

Cross-reactive..... 18, 21.
See also Cross-reactivity

Cross-reactivity..... 21, 179.
See also Cross-reactive

Crystallization19, 199, 204, 205

Cysteine.....212, 235–238, 240–241, 244, 245, 250, 254

Cytokine..... 2, 4, 15, 161, 233, 300, 304

Cytosol 266, 303

Cytotoxicity..... 196, 210, 233, 234, 248, 278, 283, 290, 295, 300–303, 307–311

D

Dendritic cells249

Desalting 197, 199, 239, 242, 280, 286

Diabodies249

Diagnostic11, 55, 172, 178, 180, 190, 209, 234

DIG. *See* Digoxigenin (DIG)

Digoxigenin (DIG)248

Dimerization 16, 22

Diphtheria toxin 33, 158

Display2, 3, 5, 12, 14–24, 33–51, 53–78, 81–99, 101–115, 145–146, 162, 261, 268

Dissociation..... 102, 103, 171, 172, 175, 177, 179, 180, 183, 186–187, 192, 235, 236, 286, 287, 289, 301, 309, 310

Dissociation rate..... 172, 177–178, 187, 189, 190, 192

Disulfide bond 9, 238, 250, 254, 257, 261

Diversification 14, 20, 138, 139, 142

Diversity12, 14, 20, 21, 23, 33, 34, 37, 78, 97, 137–139, 142, 143, 145, 146

DNA5–7, 12, 20, 24, 36, 38, 43–45, 49, 50, 54, 59, 62, 63, 67–73, 77, 78, 81, 86, 90, 96, 98, 101–108, 112, 113, 115, 139–141, 145, 152, 155–158, 211, 212, 214, 215, 218–224, 228–229, 254, 272, 279, 280, 283–285, 291, 301, 303, 306, 308

DNA fingerprinting78, 81, 86, 95–96

Drug..... 34, 53, 119, 139, 142, 158, 252

E

EBV. *See* Epstein–Barr virus (EBV)

Effector.....22, 138, 149, 150, 152, 196, 210, 211, 248, 250, 252, 277–292, 295–313

Efficacy..... 21, 146, 150, 234, 307, 312–313

EGFR. *See* Epidermal growth factor receptor (EGFR)

Electrofusion 121, 132

Electroporation.....36, 45, 46, 63

ELISA. *See* Enzyme-linked immunosorbent assay (ELISA)

E μ . *See* Enhancer (E μ)

Embryonic stem (ES) cells 140, 152

Enhancer (E μ)..... 140, 142, 144, 151, 254, 272

Enzyme-linked immunosorbent assay (ELISA).....36–38, 42, 44, 46–48, 50, 78, 81–82, 84–88, 92–95, 98, 99, 121, 123, 127–128, 131, 153, 156, 157, 164, 168–169, 171, 176, 178–179, 278–282, 286–288, 291, 292, 307

Epidermal growth factor receptor (EGFR) 16, 141, 248

Epitope.....2, 3, 12, 16, 17, 97, 128, 138, 142, 146, 178, 184, 191, 210, 235, 248, 257

Epstein–Barr virus (EBV).....162–166, 168, 170, 215, 220, 223, 272

Escherichia coli (*E. coli*) 2–3, 5, 9, 24, 35, 36, 38–40, 45–49, 51, 54, 56, 59, 67, 72, 73, 78, 96–98, 102, 103, 105, 109, 113, 145, 152, 214–216, 218, 220–223, 238, 250, 254, 272, 279, 283

Expression
cassette.....56, 57, 62, 67, 69–74, 77, 78, 96, 210, 211, 254, 268, 270, 271
vector 6, 36, 38, 42–46, 50, 109, 152, 158, 211, 214, 218, 249, 254, 257, 267, 268

Extracellular 2, 15–17, 143, 279, 281, 286–288, 292, 297, 310

F

Fab. *See* Antigen binding fragment (Fab)

FACS. *See* Fluorescence-activated cell sorting (FACS)

Fc gamma receptor IIIa (FcγRIIIa) 196, 248, 277–279, 281, 282, 290, 313

FcRn. *See* Neonatal Fc receptor (FcRn)

FDA. *See* Food and Drug Administration (FDA)

FDG. *See* Fluorodeoxyglucose (FDG)

Fixative 301

Flow cytometry..... 4, 99, 119, 121, 126–127, 169, 213, 302, 305–308, 310, 311, 313

Fluorescence 47, 196, 213, 274, 275, 302, 303, 305, 309, 310

Fluorescence-activated cell sorting (FACS) 122–123, 163, 167, 213, 218, 267–268, 274, 275, 302, 310

Fluorescent 22, 265–275, 283, 291, 300–303, 305, 308–311, 313

Fluorine-18-fluoromisonidazole (¹⁸FMISO).....313

Fluorodeoxyglucose (FDG).....313

Fluorophore.....265, 266, 273, 303

Folding 1, 20, 114, 255, 266, 268

Food and Drug Administration (FDA)..... 15, 53, 118, 119, 146, 234–236

Fragment12–15, 18–23, 34, 35, 37–42, 45, 48, 54, 56, 69, 70, 98, 140, 141, 152–156, 158, 192, 201–206, 210, 214, 218–223, 228, 229, 233–245, 249, 250, 254, 257, 266, 305

Fragmentation 196, 198, 200–201, 206

Fragment crystallizable (Fc)22, 150, 169–170, 173, 184, 209–211, 230, 233, 249, 250, 252, 257, 266, 273, 277–279, 283–285, 292, 297, 298, 302, 307, 308
domain..... 22, 230, 233, 235, 248, 252
engineering 283

Freund's adjuvant 3, 9
See also Adjuvant

Fucose..... 196, 206, 278, 292

Fusion.....9, 11, 14–15, 17, 18, 22, 42, 57, 98, 117–122, 124–126, 129, 132, 133, 140, 141, 158, 249, 254–257, 265–275, 282

Fusion protein 42, 57, 98, 268, 274, 275

G

Galactose96, 106, 299, 302

Ganciclovir 158

Gene fusion 249–250

Genetically modified mice 152
See also Genetic engineered mice

Genetic engineered mice 149
See also Genetically modified mice

Germinal centres 138

GFP. *See* Green fluorescent protein (GFP)

Glycosylated 37, 197, 202–204, 235

Glycosylation 195–206, 296

Green fluorescent protein (GFP)..... 248, 266, 268

Growth factor 16, 234, 274, 300, 305

H

Half-lives 156, 172, 177–178, 187, 192, 210, 211, 233–245, 249, 250, 266, 277, 295, 309

HAT. *See* Hypoxanthine–aminopterin–thymidine (HAT)

Heavy chain.....14, 17, 23, 54–56, 96, 138–140, 146, 150–152, 157, 195, 197, 209, 210, 237, 238, 244, 249–255, 257, 260, 261, 268, 269, 271–273, 277, 279, 280, 283, 285, 296, 297

HEK 293 cells. *See* Human embryonic kidney 293 cells (HEK 293 cells)

Helper phage36, 38, 40, 49, 54, 64, 73–76, 78, 83, 87, 89, 90, 96, 97, 279, 284

Hemagglutinin 17, 56, 92, 98, 210, 211

Hematopoietic stem cell 55

Her2. *See* Human epidermal growth factor receptor 2 (Her2)

Heterodimerization 250, 252, 254, 257, 261, 270

HGPRT. *See* Hypoxanthine-guanine phosphoribosyl transferase (HGPRT)

Hinge region 202, 209, 235, 236, 238, 244, 270, 271, 296

Homologous recombination144, 153– 156, 158

Human embryonic kidney 293 cells (HEK 293 cells).....260, 267, 270, 273

Human epidermal growth factor receptor 2 (Her2) 16, 248, 292

Humanized
 antibody..... 150, 191, 192
 mice118, 139, 147, 150
 mouse 118, 152
 Hybridoma2, 4, 8, 9, 11–13, 19, 21, 23, 24,
 33, 117–133, 142, 150, 172–176, 178–181, 247, 249
 Hydrodynamics 152–153, 156–157, 179
 Hygromycin..... 158
 Hypoxanthine–aminopterin–thymidine
 (HAT)120–122, 124–126, 132
 Hypoxanthine-guanine phosphoribosyl transferase
 (HGPRT)..... 120, 132

I

IgA165, 167, 296, 297, 299, 302, 305, 307, 308
 IgE206–208, 307
 IGF-1R. *See* Insulin-like growth factor-1
 receptor (IGF-1R)
 IgH..... 137, 138, 140–142, 144, 150–156, 158
 IgK137, 138, 140, 141, 150
 IgM13, 17, 137, 140–143, 165, 167, 296–298, 307
 IHC. *See* Immunohistochemistry (IHC)
 IL-1 α 248
 IL-1 β 248
 IL2 receptor gamma chain 312
 Imaging 234, 308
 Immobilized 3, 22, 54, 81–95, 97, 98,
 102, 131, 174, 185, 279, 282, 288, 289, 305
 Immortalization.....118, 150, 161–170
 Immune response 1, 3, 4, 13, 118, 137, 139,
 141–145, 147
 Immunization
 cell-based immunization.....2–4
 DNA immunization5
 peptide immunization2, 3
 protein immunization2–4, 18, 19, 23
 Immunoassay119, 121, 132, 187
 Immunodeficient161, 162, 312, 314
 Immunofluorescence.....23, 99, 121, 308
 Immunogen 2, 3, 5, 8
 Immunogenicity3, 24, 146, 150, 234
 Immunoglobulin (Ig).....139, 140, 151, 162, 296
 Immunoglobulin G (IgG)13, 16, 21, 22, 54,
 65, 89, 99, 106, 123, 127–129, 133, 138, 141–143,
 156, 164, 165, 167, 197–201, 209, 210, 237,
 247–261, 265–275, 277–292, 296, 297, 302, 307
 Immunohistochemistry (IHC) 121, 123, 128–129
 Immunomodulatory55
 Immunoprecipitation..... 23, 121
 Inbred mouse strain4
 Infection17, 21, 35, 38–40, 48, 54, 75,
 87, 161–165, 168, 170
 Infectious disease..... 17, 21, 53, 117, 118, 162
 Inflammatory.....3, 53, 118, 247, 305
 Influenza..... 17

Inhibition16, 21, 133, 295, 300, 304–307, 311
 Injection 3, 5, 9, 139, 152, 156, 157,
 174, 175, 179, 180, 185–187, 192, 231, 234, 249, 289,
 303, 311– 313
 Insulin-like growth factor..... 16, 274
 Insulin-like growth factor-1 receptor
 (IGF-1R)..... 16, 22, 248
 Internalization 17, 97, 170, 234, 274, 275
 In vitro
 display..... 2, 3, 12, 101, 102, 145
 selection..... 11–24
 In vivo..... 5, 18, 22, 55, 118, 139, 141,
 145–146, 152, 156, 157, 168, 210, 236, 250, 266,
 302–304, 309–313
 Isotype 131, 143, 144, 164, 211,
 230, 268, 275, 295–297, 307

J

J chain.....296, 297

K

Kanamycin.....35, 36, 49, 64, 73, 75, 76, 83, 90,
 163, 228, 229, 279, 284
 KD/Kd20, 171, 172, 177, 178, 181, 183,
 187–193, 236, 288, 289
 Kinetic 171–181, 183, 184, 186–193, 289
 Knobs-into-holes.....250–252, 254, 256–258,
 261, 269–271
 Knock-in 152, 154
 Knockout.....140, 145, 278, 312

L

Labeling 109, 126, 127, 184, 299, 302, 303, 306, 310
 Lactate dehydrogenase (LDH)..... 290, 301, 307, 309
 Library.....13, 14, 18, 20, 23, 34, 37, 38,
 41, 48, 49, 54–56, 63, 72–78, 81–84, 86, 87, 89–93,
 97, 98, 101–103, 107, 110, 114, 115, 145, 162
 Ligand15, 16, 22, 48, 102, 121, 133, 161,
 236, 237, 295, 299, 300, 302–305
 Ligation.....34, 38, 44, 45, 57, 62, 63, 67,
 71–75, 77, 78, 98, 113, 219, 220, 222, 229
 Light chain 14, 21, 23, 54, 56, 71, 78,
 85, 94, 98, 131, 138, 139, 150, 151, 157, 192, 209,
 210, 237, 238, 249–255, 257, 260, 261, 267–269,
 273, 275, 280, 282, 285, 292, 296, 302
 Linker..... 14, 22, 210, 212, 238, 250,
 254–257, 261, 266, 268–270
 LoxP (Cre recombinase), 155
 Lymphocyte..... 15, 58, 64, 117, 125, 132,
 133, 137, 153, 169, 312
 Lymphoma 161, 213, 282, 283, 292, 312
 Lysine..... 2, 97, 197, 235
 Lysis6, 8, 111, 255, 278, 290, 291, 295,
 304, 307, 309–311, 313

M

mAb. *See* Monoclonal antibody (mAb)
 Macrophage..... 248, 249, 278, 300, 304, 310, 312
 Major histocompatibility complex (MHC)18
 Mammalian cell..... 211, 215–217, 223, 253–255,
 260, 265–275
 Mass spectrometry (Mass
 spectroscopy) 2, 8, 109, 195–206, 261, 275
 Maturation 13, 18, 20, 21, 55, 118, 138,
 139, 141, 142, 144, 145, 147, 153
 MHC. *See* Major histocompatibility complex (MHC)
 Mice. *See* Mouse (mice)
 Monoclonal antibody (mAb).....2–4, 8, 9, 11, 15, 33,
 53–55, 99, 101, 117–133, 139, 142, 146, 150,
 161–170, 186, 195, 209–231, 243, 247–249, 295,
 300, 302, 305–309, 311–313
 Mononuclear3, 55, 58, 64, 65, 77, 163, 166,
 168, 300, 301, 304, 310
 Monovalent 15, 16, 54, 99, 234, 236, 237, 250, 252
 Mouse (mice)..... 4, 8, 9, 12, 18, 21, 23, 84, 85, 93,
 118, 119, 122–125, 127–129, 132, 133, 137–147,
 150–158, 162, 173, 174, 176, 178, 184, 185, 192, 211,
 212, 230, 234, 249, 281, 300, 302, 303, 306, 311–314
 mRNA..... 13, 34, 55, 102–104, 108–114, 153
 MTS assay..... 300, 303, 306
 MTT assay..... 299, 303
 Mutagenesis..... 20, 36, 279, 283, 284, 291
 Mycoplasma 131
 Myeloma 11, 117, 120–122, 124–126, 132

N

Natural killer (NK) cells248, 249, 278, 290,
 298, 300, 304, 312
 Neomycin 154, 155, 158
 Neonatal Fc receptor (FcRn).....235, 277–292, 298, 313
 Neutralization.....39, 295, 297, 298
 Neutralizing antibody..... 146
 Neutravidin..... 2, 3, 37, 46, 47, 49, 50, 281, 286, 291
 Neutrophils.....248, 278, 298, 304
 Next generation sequencing (NGS) 22–24
 NOD. *See* Nonobese diabetic (NOD)
 NOD-Rag1^{null} IL2Rg^{null} 302, 312
 NOD-scid 302, 312
 NOD/SCID..... 302–313
 NOD-scid IL2Rg^{null} 302, 312
 Nonobese diabetic (NOD) 302, 312, 313
 Nude.....312

O

Oligosaccharide 195–197, 199–202, 204, 205

P

Panning 2, 34–43, 46, 48–50, 54, 74, 75, 78,
 81, 86– 92, 94, 97, 98, 102

Payload delivery.....248
 PBMC. *See* Peripheral blood mononuclear cells (PBMC)
 pCANTAB..... 6, 103, 104, 106, 107, 114
 PCR. *See* Polymerase chain reaction (PCR)
 PEG. *See* Polyethylene glycol (PEG)
 PEGylation 233–245
 Penetration 233, 234, 249
 Peptide..... 2, 3, 5, 9, 14, 22, 34, 56, 97, 102,
 103, 106, 197, 198, 201, 206, 212, 250, 253–255, 261,
 269–272, 299, 302, 303
 Peripheral blood mononuclear
 cells (PBMC)..... 3, 55, 58, 64–65, 76, 77,
 163–168, 300, 301, 304, 308–310
 Perioplasm 9, 56, 98
 PET. *See* Positron emission tomography (PET)
 Phage..... 2, 5, 12–24, 33–51, 53–78, 81–99,
 101, 103, 114, 145–146, 162, 210, 279, 284
 Phage display..... 2, 5, 12–24, 33–51, 53–78, 81–99, 114,
 145–147, 162
 Phagemid 14–15, 34, 43, 54, 56, 57, 62, 69,
 71, 73, 74, 78, 81, 94–97
 Phagocytosis 297, 310–311
 PI. *See* Propidium iodide (PI)
 Plasmid..... 5–7, 12, 43, 49, 63, 69, 70, 103,
 106, 152–155, 157, 212–216, 218–226, 229, 253,
 254, 260, 273, 279–280, 283–285
 PMN. *See* Polymorphonuclear leukocyte (PMN)
 Polyethylene glycol (PEG) 36, 41, 64, 74, 83, 90,
 105, 113, 120–122, 124, 126, 132, 205, 235–245,
 250, 279, 284
 Polymerase chain reaction (PCR).....20, 23, 56, 57,
 59–62, 66–70, 77, 78, 82, 86, 96, 101–109, 111–115,
 152–156, 254, 272, 291
 Polymerization..... 296
 Polymorphism 278, 291
 Polymorphonuclear..... 65, 304
 Polymorphonuclear leukocyte (PMN).....304
 Polypeptide 3, 14, 56, 114, 121, 123, 127,
 197, 210, 213, 255, 261
 Positron emission tomography (PET)..... 6, 313
 Preclinical 211, 234, 236, 237, 248, 295
 Prkdc^{scid}. *See also* Severe combined
 immunodeficient (SCID) 302
 Promoter.....34, 49, 56, 103, 104, 114, 140,
 152, 254, 270–272
 Propidium iodide (PI) 181, 299–303, 306, 307, 310, 311
 Protein
 expression 2, 6, 7, 267, 268
 purification 7, 8
 Protein A 210, 211, 213, 217–218,
 226–228, 230, 253–255, 260, 267, 273
 Puromycin 12, 158

Q

Quadroma 249

R

Rabbit.....8–9, 173, 184, 185, 211
 Radioactive..... 302, 309, 313
 RAG. *See* Recombination activating gene (RAG)
 Rat.....78, 84, 85, 92, 94, 95, 97, 98, 131,
 213, 218, 235, 249
 RD. *See* Ribosomal display (RD)
 Recombinant protein..... 2, 9, 156
 Recombination activating gene (RAG)312
 Recombineering 144
 Repertoire..... 13, 14, 23, 24, 53–55,
 118, 137–139, 141–142, 145, 150, 161–170, 250
 Replacement..... 144, 150, 153, 155, 256
 Ribosomal display (RD) 34, 101–115.
See also Ribosome display
 Ribosome.....12, 54, 56, 102, 103, 109, 110, 114
 Ribosome display..... 101, 102.
See also Ribosomal display (RD)
 RNA..... 19, 55, 58–59, 65–67, 77,
 103–105, 108, 111, 114
 RT-PCR..... 56, 59–62, 66–69, 102, 109

S

scFv. *See* Single-chain variable fragment (scFv)
 SCID. *See* Severe combined immunodeficient (SCID)
 Screening.....3–5, 12, 22, 23, 34, 36–38, 42,
 44, 46–47, 50, 102, 118–123, 126–130, 132, 133,
 142, 145, 155, 162, 164, 168–169, 171–181, 185
 SDS-PAGE..... 213, 228, 231, 241–245, 260, 273
 Selection3, 5–7, 11–24, 33–41, 43, 46, 48,
 50, 54, 55, 74– 76, 78, 81–99, 101, 102, 105–106,
 108–115, 121, 130, 138, 139, 146, 155, 158, 169, 171,
 172, 176, 180, 183–193, 196, 228, 252, 261, 272
 Sequencing 20, 22–24, 47, 61, 81, 86,
 95–96, 98, 119, 155, 215, 220, 223, 285
 Serum 2, 4, 6, 11, 19, 33, 64, 82, 84, 92, 97,
 122– 125, 129, 133, 140–144, 153, 156, 163, 213,
 217, 218, 225, 226, 237, 250, 253, 266, 267, 280, 283,
 290, 291, 297–300, 307
 Serum half-life 237, 266
 Severe combined immunodeficient (SCID)312
See also Prkdc^{scid}
 SH2 18, 23
 Single-chain variable fragment (scFv) 13, 14, 16,
 18, 20, 22, 23, 48, 54, 99, 102–104, 106, 107, 109,
 110, 114, 209–231, 249–251, 254–255, 261
 Specificity14, 15, 17–18, 20, 21, 23, 24, 55,
 97, 99, 121, 139, 142, 145, 149, 150, 176, 184, 209,
 210, 250, 254–256, 295, 307
 Splenocyte 120–122, 124–126
 SPR. *See* Biacore; Surface plasmon resonance (SPR)
 Stability 20, 24, 103, 113, 172, 175–176, 178, 181, 184,
 187, 190, 193, 195, 206, 237, 244, 249, 250, 261, 266
 Statistic..... 181, 249

Stem cell..... 55, 152, 282, 283, 300
See also Embryonic stem (ES) cells;
 Hematopoietic stem cell
 Streptavidin 2, 3, 35, 38, 48, 49, 105, 109, 111,
 213, 218, 281, 286, 287
 Subcloning..... 13, 21, 36, 42–46, 109, 118,
 120, 121, 124, 129–130, 133, 268
 Subcutaneous..... 9, 312
 Sulfotyrosine..... 19
 Surface plasmon resonance
 (SPR)..... 99, 171, 179, 192, 235, 236,
 261, 273, 279, 282, 288–289, 300, 305, 307
See also Biacore
 Syngeneic 4, 312, 314

T

Tag.....5, 6, 8, 9, 22, 37, 97, 98, 104, 109,
 210–212, 281, 282, 287, 291, 292, 310
 TALEN. *See* Transcription Activator-Like Effector
 Nucleases (TALEN)
 Target 2–5, 11, 12, 15–18, 20–24, 33, 34,
 103, 105, 109, 128, 133, 145, 150–156, 158, 179, 198,
 199, 233–235, 248, 249, 252, 253, 274, 278, 279, 282,
 283, 290–292, 295, 297, 299–311, 314
 T cell146, 237, 248, 249, 278, 280, 285, 312
 Therapeutic antibody (monoclonal
 antibody)..... 117, 137–147, 172, 186–189,
 196, 234, 237, 252, 290, 295–314
 Therapeutics..... 11, 21, 22, 33, 55, 117–119,
 136–147, 172, 196, 209, 233, 234, 236, 247–249,
 253, 277, 278, 295–314
 Thiol.....235, 244
 Thymidine kinase (TK).....158
 Titration 39–42, 129, 287, 288, 290
 TLR. *See* Toll-like receptor (TLR)
 TNF α . *See* Tumor necrosis factor alpha (TNF α)
 Toll-like receptor (TLR) 145, 161, 162, 164
 Toxicity 21
 Transcription 102, 103, 105, 107, 108,
 111, 114, 115, 144, 150, 152, 153, 161
 Transcription Activator-Like Effector
 Nucleases (TALEN).....152
 Transfection..... 152, 155, 156, 169, 211,
 215–217, 223–226, 229, 230, 253, 260, 273, 280, 285
 Transformation 5–7, 38, 45, 46, 50, 54,
 62, 63, 67, 71–73, 75, 78, 101, 145, 162, 219, 222
 Transgene139–141, 143, 150, 151, 153, 156, 157
 Transgenic 12, 118, 119, 137–147, 153, 156, 162, 313
 Tumor..... 13, 15, 16, 18, 22, 55,
 234, 248, 249, 295, 302, 303, 305–309, 311–314
 cell 16, 22, 55, 248, 249, 302,
 303, 306, 307, 311, 312
 graft.....312
 models 312
 Tumor necrosis factor alpha (TNF α)15, 141, 146, 235

U

U937 cells 301, 310

V

Vaccine 55

Variable heavy (VH) 12, 14, 17,
 22, 23, 56, 57, 59–61, 66–74, 77, 78, 96, 112, 114,
 139–142, 144, 209, 210, 213, 250–252,
 254–257, 261

Variable light (VL) 12, 14, 22, 23, 56, 59–62,
 66–69, 74, 78, 96, 114, 139, 209, 210, 250–252,
 254–257, 261

Vascular endothelial growth factor
 (VEGF) 21, 234, 248, 292

Vascular endothelial growth factor receptor1
 (VEGFR1) 248

Vascular endothelial growth factor receptor2
 (VEGFR2) 248

VEGF. *See* Vascular endothelial growth factor
 (VEGF)

VEGFR1. *See* Vascular endothelial growth factor receptor1
 (VEGFR1)

VEGFR2. *See* Vascular endothelial growth factor receptor2
 (VEGFR2)

Virus 5, 13, 17, 54, 163, 164, 168, 272, 295, 297

W

WIL2-S B lymphoma cells 282, 283, 292

Y

Yeast artificial chromosome (YAC) 140–142, 150

Yellow fluorescent protein (YFP) 265

Z

Zeocin 158

Zinc finger nuclease (ZFN) 152